Abstract 240P
Background
Cervical cancer is one of the leading causes of morbidity and mortality among women from cancer of the reproductive organs in developing countries. The purpose of this study is to analyze the dynamics of morbidity and mortality from cervical cancer in the Republic of Kazakhstan.
Methods
Mortality and morbidity rates were calculated for the period 2007-2016. 95% confidence intervals are presented. Incidence of and mortality rates were calculated per 100,000 (0/0000) of female population. All statistical calculations were performed using SPSS (Statistical Package for the Social Sciences) software, version 20.0 for Windows.
Results
For the period from 2007 to 2016, the incidence rates of cervical cancer were analyzed, which varied from 15.24 to 18.83 per 100,000 of female population. Mortality rates tended to decline over the 10-year period under review in 2007, reaching 7.8 to 7.0 per 100,000 of female population in 2016. There is a difference in morbidity and mortality from cervical cancer between different regions of Kazakhstan. An analysis of the distribution of the incidence in the Republic of Kazakhstan revealed the highest incidence rates in the northern region of the country 28.2 (95% CI: 23.6-33.5) and the north-eastern region 27.3 (95% CI: 22.4-32.9) per 100,000 of female population. On the other hand, the lowest morbidity and mortality rates were found in the southern region substituted 10.4 (95% CI: 7.4-14.2) and 5.4 (95% CI: 4.3-6.8) per 100,000 of female population respectively.
Conclusions
Thus, the incidence of cervical cancer in the Republic of Kazakhstan has increased over the 10-year period in question, while mortality rates have been gradually decreasing. Such trends can result from the national screening program which was implemented in Kazakhstan.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
195P - HGCSG1601: A retrospective cohort study of the efficacy and safety of nab-paclitaxel plus gemcitabine (nab-P+GEM) for unresectable locally advanced pancreatic cancer (LAPC)
Presenter: Aya Tanimoto
Session: Poster display session
Resources:
Abstract
196P - The tolerability and efficacy of FOLFIRINOX in gastro-oesophageal carcinoma
Presenter: Nicholas Travers
Session: Poster display session
Resources:
Abstract
197TiP - GLOW: Zolbetuximab + CAPOX compared with placebo + CAPOX as first-line treatment for patients with Claudin18.2+/HER2– Locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma: A randomized phase III study
Presenter: Rui-Hua Xu
Session: Poster display session
Resources:
Abstract
198TiP - SPOTLIGHT: Comparison of zolbetuximab or placebo + mFOLFOX6 as first-line treatment in patients with claudin18.2+/HER2– locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma (GEJ): A randomized phase III study
Presenter: Kensei Yamaguchi
Session: Poster display session
Resources:
Abstract
199TiP - Phase III (COSMIC-312) study of cabozantinib (C) in combination with atezolizumab (A) vs sorafenib (S) in patients (pts) with advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy
Presenter: Thomas Yau
Session: Poster display session
Resources:
Abstract
200P - Apalutamide (APA) plus androgen deprivation therapy (ADT) for metastatic castration-sensitive prostate cancer (mCSPC): Analysis of pain and fatigue in the TITAN study
Presenter: Byung Ha Chung
Session: Poster display session
Resources:
Abstract
201P - Efficacy and safety of darolutamide in non-metastatic castration-resistant prostate cancer (nmCRPC) in the ARAMIS trial
Presenter: Jacob See-tong Pang
Session: Poster display session
Resources:
Abstract
202P - What is the best first-line therapy for metastatic castration-sensitive prostate cancer in 2019? A network meta-analysis
Presenter: Tsz Him So
Session: Poster display session
Resources:
Abstract
203P - Long term outcomes of 2-weekly docetaxel in metastatic high-volume hormone sensitive prostate cancer
Presenter: Suhas Singla
Session: Poster display session
Resources:
Abstract
204P - The effect of radium-223 therapy in agent orange related veterans with metastatic castrate resistance prostate carcinoma (CRPC)
Presenter: Andrew Liman
Session: Poster display session
Resources:
Abstract